Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Continuous glucose monitoring: transforming diabetes management step by step

The introduction and evolution of continuous glucose monitoring (CGM) has transformed how glucose control is defined and approached. Glycated haemoglobin (HbA1c) remains the key surrogate for the risk of microvascular complications and a good comparator of average glycaemic control in different populations. But use of HbA1c alone to guide diabetes management can be misleading.1 With the high clinical burden and cost associated with substantial hypoglycaemia,2 a better approach to optimal glycaemic management might be HbA1c combined with a measure of hypoglycaemia.